159
Participants
Start Date
May 4, 2017
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
Mepolizumab
It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
GSK Investigational Site, Clayton
GSK Investigational Site, Woodville South
GSK Investigational Site, Nedlands
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Rochester
GSK Investigational Site, Rüdersdorf
GSK Investigational Site, Baltimore
GSK Investigational Site, Schleswig
GSK Investigational Site, Orangeburg
GSK Investigational Site, Albany
GSK Investigational Site, Miami
GSK Investigational Site, Aventura
GSK Investigational Site, Birmingham
GSK Investigational Site, Cincinnati
GSK Investigational Site, Evansville
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, St Louis
GSK Investigational Site, Colorado Springs
GSK Investigational Site, Scottsdale
GSK Investigational Site, Los Angeles
GSK Investigational Site, San Diego
GSK Investigational Site, Medford
GSK Investigational Site, Voronezh
GSK Investigational Site, Chelyabinsk
GSK Investigational Site, Piscataway
GSK Investigational Site, Sherwood Park
GSK Investigational Site, Toronto
GSK Investigational Site, Windsor
GSK Investigational Site, Saint-Charles-Borromée
GSK Investigational Site, Leipzig
GSK Investigational Site, Linköping
GSK Investigational Site, Lund
GSK Investigational Site, Leicester
GSK Investigational Site, Bradford
GSK Investigational Site, Oxford
GSK Investigational Site, Plymouth
GSK Investigational Site, Southampton
Lead Sponsor
GlaxoSmithKline
INDUSTRY